Kornimate/medical-research-clean huggingface dataset:
puva versus puva + ifn alpha 2a in mycosis fungoides

Conditions: Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Summary: the purpose of this study is to determine if combination of puva with interferon alpha is better than puva alone to treat mycosis fungoides stage ia ib or iia.


Eligibility criteria:
inclusion criteria: * mycosis fungoides stage ia ib iia * written informed consent * 18-70 y.o., both sex * no concomitant systemic disease exclusion criteria: * pregnant or lactating women * fertile women not accepting contraception * medical history of melanoma or non melanoma skin cancer * concomitant infections * immunodeficiency states * previous heart disease * respiratory insufficiency * chronic rrenal insufficiency * chronic hepatopathy * epilepsy * depression * leucocytes \<3000 or neutrophiles \<1000 or thrombocytes \<100000 or hemoglobin \<12 gr/dl or ana \<1/80 * treatment with systemic steroids * altered thyroid hormones * previous resistance to puva and/or ifn * hypersensitivity to ifn * patients under treatment with teophiline and/or dicumarol * previous total skin electron beam * wash up period less than 3 month for ifn and /or puva * wash up period less than 1 month for topical treatments
comparison of the effects of tfpb and anterior qlb on postoperative analgesia in cesarean section surgery

Conditions: Analgesia; Acute Pain; Chronic Pain

Summary: this study evaluates the postoperative analgesic effects of transversalis fascia plane block and anterior quadratus lumborum block in patients having cesarean section under general anesthesia. general anesthesia will be performed to all patients for the surgery.

in this study, patients are divided into two groups. after the general anesthesia is performed and cesarean section surgery is over; tfpb block will be performed to patients in group a ; while anterior qlb block will be performed to patients in group b. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively. group a - patients in group a will have tfpb block after the surgery. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively. group b - patients in group b will have anterior qlb block after the surgery. in addition, patient controlled analgesia (pca) will be used in the first 24 hours postoperatively.

Eligibility criteria:
inclusion criteria: * being pregnant for at least 37 weeks * planning an elective cesarean operation * being between the ages of 18-45 exclusion criteria: * american society of anesthesiologists (asa) 3-4 patients with comorbidities (serious renal, cardiac, hepatic disease) * being operated with spinal anesthesia * obesity (\> 100 kg, bmi\> 35 kg / m2) * contraindication of regional anesthesia (coagulopathy, abnormal international normalized ratio (inr), thrombocytopenia, infection at the injection site) * hypersensitivity to local anesthetics or a history of allergy * patients with a history of opioid use longer than four weeks * patients with psychiatric disorders * patients with anatomic deformity * patients who do not want to participate

Keywords: regional anesthesia acute and chronical pain transversalis fascia plane block quadratus lumborum blocks cesarean section
copeptin as a biomarker for central diabetes insipidus development following pituitary surgery

Conditions: Sellar and Suprasellar Masses; Pituitary Tumor

Summary: 1. access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2. access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy 3. access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

patient serum levels of copeptin would be measured after phlebotomy of 3 ml of blood in edta tube twice a) within 1-4 hours of extubation and b) within 4-24 hours of extubation (the morning following surgery).

Eligibility criteria:
inclusion criteria: \* patients with sellar and suprasellar masses who undergo neurosurgical procedure at mayo clinic rochester. exclusion criteria: \* patients with preexisting cdi.
omega-3 and blueberry supplementation in age-related cognitive decline

Conditions: Age-related Memory Disorders; Mood Disorders

Summary: the aim of this study is to determine the efficacy of 6 months' dietary supplementation with omega-3 fatty acids and whole freeze dried blueberry powder in improving cognition in older adults. the effects of each of these interventions alone will also be assessed in order to determine whether the combined treatment confers synergistic or additive benefit relative to the effect of each therapy.

after meeting inclusion criteria, one hundred-forty men and women, aged 62 to 80 years old, will be enrolled and randomly assigned to one of four groups: 1) omega-3 fatty acid and blueberry powder supplement, 2) omega-3 fatty acid and placebo powder, 3) placebo oil and blueberry powder supplement, or 4) placebo oil and placebo powder. they will participate in a 24-week intervention with major assessments including neuropsychological and functional evaluation at pre-treatment baseline and during the final week of the intervention. in addition, an interim evaluation of neurocognitive function will be conducted at 12 weeks. subjects will be asked to maintain diet diaries for three periods during the study. mood will be assessed as a potential covariate of the neurobehavioral outcome measures and data on red blood cell fatty acid content, metabolic parameters, inflammation, and anthropometric factors will be gathered to assess compliance and explore individual differences in response to the intervention and to evaluate potential mechanisms of action.

Eligibility criteria:
inclusion criteria: * men and women aged 62 to 80 years and older * age-associated decline operationalized as clinical dementia rating = 0, auditory verbal learning test cumulative acquisition score between 1.0 standard deviation below and 1.0 standard deviation above the age-corrected mean or montreal cognitive assessment score greater than 25, and geriatric depression scale score less than 16 * ability to comprehend and comply with the research protocol * provision of written informed consent. exclusion criteria: * established dementia or neurological disorder including but not limited to probable alzheimer's disease, parkinson's disease, frontotemporal dementia, multi-infarct dementia, and leukoencephalopathy * current or past severe psychiatric disorder such as psychosis or major mood disorder requiring hospitalization and/or causing a change in level of occupational or social functioning * current or past alcohol or drug abuse disorder causing physiological dependence or change in functional capability (nicotine dependence is permitted) * diagnosis of diabetes or other metabolic disorder or kidney or liver disease * use of medication that might affect outcome measures or interact with omega 3 fatty acid supplements such as benzodiazepines, aspirin, and serotonin reuptake inhibitors * hematological coagulation disorder * allergy to shellfish or seafood; 8) current supplementation with fish oil or consumption of fish more than once per week.

Keywords: working memory long-term memory neurocognition dietary supplementation dementia
tranexamic acid in hip fracture patients

Conditions: Closed Fracture of Hip

Summary: this is a randomized controlled trial comparing the use of tranexamic acid to placebo in patients admitted to hospital with a hip fracture.

1. transfusion of allogeneic rbc's is not free of adverse events and has been associated with an increased risk of postoperative infection 2. tranexamic acid in trauma patients has been shown to reduce 30-day mortality. hospital trauma protocol includes tranexamic acid in patients with major bleeding. 3. tranexamic acid in orthopedic elective joint reconstruction surgery has been shown to substantially decrease bleeding in knee and hip arthroplasty. 4. in hip fracture surgery, transexamic acid reduces erythrocyte transfusion rate but may promote a hypercoagulable state. 5. tranexamic acid is an antifibrinolytic drug that inhibits plasminogen from turning into plasmin thereby inhibiting clot breakdown.

Eligibility criteria:
inclusion criteria: * patients admitted to the emergency room with proximal hip fractures (31a-31b according to the muller ao classification of fractures - long bones). * patients mentally capable of giving informed consent. exclusion criteria: 1. vascular events within the last 2 months such as cva, tia, acs, mi, dvt or arterial thrombosis. 2. patients receiving anticoagulation therapy with coumadin or plavix. 3. pregnancy and breastfeeding females. 4. previous arterial or venous thrombosis 5. history of seizures. 6. creatinine \>2. 7. oestroprogestive therapy. 8. multiple fractures.

Keywords: proximal hip fractures
next generation ophthalmic irrigating solution posterior segment study

Conditions: Eye Diseases

Summary: the purpose of this study is to evaluate the safety of next generation ophthalmic irrigating solution (ngois) compared to bss plus for use during surgery for removal of epimacular membrane and vitrectomy.


Eligibility criteria:
inclusion criteria: * patients of any race and sex, with an epimacular membrane who would benefit from vitrectomy and membrane removal. * other protocol-defined inclusion criteria may apply. exclusion criteria: * under 18 years of age. * other protocol-defined exclusion criteria may apply.

Keywords: epimacular membrane
two approaches in enhancing the efficacy of inferior alveolar nerve block during treatment of mandibular first permanent molars with symptomatic irreversible pulpitis

Conditions: Pain, Procedural

Summary: the study is designed as a randomized parallel controlled trial with three groups. participants aged above 18 years with the first permanent molars with symptomatic signs of irreversible pulpitis will be randomly assigned into 3 groups. the first group (experimental group) will be injected with 4% articaine 1:100.000 epinephrine (inferior alveolar nerve block) will be anesthetized using 4% articaine 1:100.000 plus cryotherapy application, and the second group (experimental group) will be anaesthetised with ianb plus buccal infiltration. for the third group (control group), the mandibular molars will be anaesthetized using epinephrine using the inferior alveolar nerve block.


Eligibility criteria:
inclusion criteria: * patients aged above 18 years * presence of at least one mandibular first permanent molar, with signs and symptoms of irreversible pulpititis exclusion criteria: * participants with a history of taking medications that could interfere with the action of the anaesthetic solutions * presence of paresthesia * presence of psychological problems * taking analgesics or other medications that would alter the inflammatory response of the pulp or provide analgesia 12 h pre-operatively
a comparison between dexmedetomidine and propofol-fentanyl infusions for sedation for colonoscopy procedures

Conditions: Anxiety and Fear

Summary: background: different intravenous sedative drugs have been utilized for colonoscopy, with many anesthetists for painless sedation or monitored anesthesia care. the aim of this study was the quality of colonoscopy and the incidence of adverse events such as respiratory depression, hemodynamic instability, and failure to provide adequate sedation.

background: different intravenous sedative drugs have been utilized for colonoscopy, with many anesthetists for conscious sedation or monitored anesthesia care. aim of this study was the quality of colonoscopy and the incidence of adverse events such as respiratory depression, hemodynamic instability, and failure to provide adequate sedation. patients and methods: sixty patients of both sexes and 21-60 years old with asa physical status i-ii, were randomly assigned to receive either dexmedetomidine (d group) or propofol-fentanyl (pf group) infusions in equal numbers. minimal infusion rates of dexmedetomidine (0.1-0.4 μg/kg/h) in the d group and fentanyl (0.01-0.05 μg/kg/min) in the pf group were continued during colonoscopy, which lasted approximately 30 minutes.

Eligibility criteria:
* inclusion criteria: 1. both sexes 2. 21-60 years old, with 3. asa physical status - * exclusion criteria: * severe cardiovascular or respiratory disease * (asa grade ≥iii) * pregnancy * allergies to the drugs being used * known alcohol or substance abuse * expected communication difficulties with the patient.
eosinophilic esophagitis databank

Conditions: Esophagitis; Eosinophilic Esophagitis

Summary: this study will establish a registry for participants with eosinophilic esophagitis (eoe) and create a research resource that will provide further insights into eoe.

eosinophilic esophagitis (eoe) is a newly recognized chronic disease that is increasingly being diagnosed in children and adults. many patients with eoe also have food allergies. eoe is characterized by inflammation and accumulation of a specific type of immune cell, called an eosinophil, in the esophagus. while there have been several large studies of eoe, very few have focused on the roles the immune system, genetics/heredity, and the environment in eoe. the samples and information collected from participants will help to identify and understand the genetic mechanisms underlying eosinophilic esophagitis. the cincinnati children's hospital medical center will serve as the central laboratory for genetic characterization studies.

Eligibility criteria:
inclusion criteria: * written informed consent/assent from participant and consent from parent/guardian for minors with agreement for genetic testing; * documented diagnosis of eoe at any time confirmed by study team (pathology report describing greater than or equal to 15 eosinophils/hpf in peak field of an esophageal biopsy. participants with eosinophilia in extra-esophageal tissue are permitted). exclusion criteria: * participants with known infectious causes of esophageal eosinophilia such as esophageal fungus, gastric h. pylori, or systemic parasites; * participants with a history of persistent eosinophilia greater than 1500 cells/mcl of blood.

Keywords: eosinophilic esophagitis
a phase ii clinical trial to evaluate hlx208 in advanced melanoma patients with braf v600 mutation

Conditions: Advanced Melanoma

Summary: an open-label, multicenter phase ii clinical study to evaluate safety, efficacy and pk of hlx208 for advanced melanoma with braf v600 mutation


Eligibility criteria:
inclusion criteria: * age\>=18y * good organ function * expected survival time ≥ 3 months * advanced melanoma with braf v600 mutation that have been diagnosed * ecog score 0-1; exclusion criteria: * previous treatment with braf inhibitors or mek inhibitors * symptomatic brain or meningeal metastases (unless the patient has beenon \> treatment for 3 months, has no evidence of progress on imagingwithin 4 weeks prior to initial administration, and tumor-related clinicalsymptoms are stable). * severe active infections requiring systemic anti-infective therapy * a history of other malignancies within two years, except for cured carcinoma in situ of the cervix or basal cell carcinoma of the skin.
counseling among gender diverse adolescents who use depot medroxyprogesterone

Conditions: Gender Dysphoria, Adolescent

Summary: recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (tgd) youth compared to cis-gender youth. limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. the investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for tgd youth. the investigator will recruit transgender youth who are assigned female at birth, and currently or interested in using depo medroxyprogesterone (dmpa). through focus groups and semi-structured interviews, the investigator hopes to guide providers in creating best practices and more equitable contraceptive counseling for tgd youth and measure satisfaction of dmpa in tgd youth.

recommendations regarding contraceptive counseling and reproductive health differ amongst transgender and gender diverse (tgd) youth compared to cis-gender youth. tgd youth face unique health disparities including increased risk of sexually transmitted infections, sexual abuse and violence, and unwanted pregnancies. tgd youth also face inequities within the healthcare system including lack of access to providers and delay or avoidance of care. both patients and providers also have misconceptions around pregnancy risk in transgender individuals assigned female at birth (afab) who are sexually active with people assigned male at birth. limited existing literature demonstrates the need for contraceptive counseling that moves beyond cis- and heteronormative assumptions that start with pregnancy prevention and address concerns at the intersection of gender identity. the investigator's qualitative study will focus on creating best practices regarding equitable contraceptive counseling for tgd youth. the investigator will recruit transgender youth who are afab, and currently or interested in using depo medroxyprogesterone (dmpa). through focus groups and semi-structured interviews, the investigator hopes to gain the perspectives of and experiences of tgd youth with self-and clinic- administered dmpa. the investigator hopes the results of this study can guide providers in creating best practices and more equitable contraceptive counseling and measure to satisfaction of dmpa for tgd youth.

Eligibility criteria:
inclusion criteria: * between the ages of 15-21, * currently receiving care at one of the clinic sites, assigned female at birth, identify as transgender or gender diverse , and are currently using or are interested in using dmpa. exclusion criteria: * any contraindications to dmpa (based on any category 3 or 4 recommendations from the cdc mec guidelines)
xelox combined with cadonilimab versus xelox as neoadjuvant treatment for locally advanced, pmmr rectal cancer

Conditions: Rectal Cancer; MSS

Summary: this is a two-arm, open label, randomized phase ii clinical study. the aim is to evaluate the safety and efficacy of cadonilimab (a pd-1/ctla-4 bispecific antibody) combined with xelox regimen in pmmr locally advanced rectal cancer during the perioperative period. eligible patients will receive either cadonilimab plus xelox or xelox alone for 4 cycles before and 4 cycles after surgery. the primary endpoint is the pathological complete response rate.


Eligibility criteria:
inclusion criteria: * histologically or pathologically confirmed rectal adenocarcinoma located within 5 to 15cm from the anus with a stage of t3-4a or n+ according to the ct or endoscope * mesorectal fascia uninvolved * sign the informed consent form * 18 years and older * mismatch repair proficient determined by immunohistochemistry * no prior treatment * performance status: ecog 0-1 * good organ function: blood routine: hemoglobin ≥90g/l, neutrophil ≥1.5×10\^9/l, platelet ≥100×10\^9/l; renal function: creatinine≤1.5×upper limit of normal (unl) or creatinine clearance ≥50ml/min; liver function: total bilirubin (tbil)≤1.5×upper limit of normal (unl); alt≤2.5×unl, ast≤2.5×unl; ejection fraction at least 50% (or lower limit of normal) by echocardiogram exclusion criteria: * other pathological category, such as squamous cancer * distant metastasis or peritoneum implantation * have received chemotherapy or radiotherapy in the past * known to have allergic reactions to any ingredients or excipients of experimental drugs * unable to swallow or under other circumstance which would drug absorption * other active malignant tumors, excluding those who have been disease free for more than 5 years or in situ cancer considered to have been cured by adequate treatment * have received colorectal cancer surgery * diabetes was not controlled, defined as hba1c \> 7.5% after anti-diabetic drugs or hypertension was not controlled, defined as systolic / diastolic blood pressure \> 140 / 90 mmhg after antihypertensive drug * myocardial infarction, severe/unstable angina, new york heart association (nyha) class iii or iv congestive heart failure in the past 12 months * known to be infected with human immunodeficiency virus (hiv), have acquired immunodeficiency syndrome (aids) related diseases, have active hepatitis b or hepatitis c * pregnant or nursing * may increase the risk associated with participation in the study or administration of the study drug or mental illness that may interfere with the interpretation of research results * there are other serious diseases that the researchers believe patients cannot be included in the study
a bidirectional study in exploring the dynamic changes of plasma and urine metabolites of nasopharyngeal carcinoma.

Conditions: Nasopharyngeal Carcinoma; EBV Infection

Summary: the transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway. therefore, we carried out this study to explore the changes of plasma and urine metabolites at different stages during the occurrence and development of nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: * ebv virus infector: qpcr/ebv antibody, diagnosed as ebv infection patient with previous infection; * nasopharyngeal carcinoma patients:patients diagnosed as nasopharyngeal carcinoma by pathological diagnosis (2018 who standard); * healthy people: healthy people who have no history of nasopharynx related diseases or other known diseases that may affect blood lipid/protein metabolism and have been hospitalized in the physical examination center of southern hospital. exclusion criteria: 1. people who have a history of non research related liver diseases or other diseases known to affect blood metabolism (except for controlled type ii diabetes); 2. have a history of other malignant tumors, except for fully treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ; 3. diseases requiring long-term use of immunosuppressive drugs (including steroids), including but not limited to congenital or acquired immunodeficiency diseases or active central nervous system metastatic cancer, active infection or uncontrolled heart disease; 4. suffer from other uncontrolled serious diseases at the same time, such as unstable heart disease requiring treatment, diabetes with unsatisfactory control (fasting blood glucose\>1.5 × upper limit of normal value), mental illness and severe allergic history. 5. bmi is less than 18 or more than 25. -
endocrine outcome of surgery for pituitary adenoma

Conditions: Pituitary Adenoma

Summary: prospective and randomized compare between microsurgical and endoscopic transsphenoidal mri assisted resection of pituitary adenomas.

the main aim of the study is to compare microsurgical and endoscopic transsphenoidal surgery and to determine endocrine outcome. secondary extent of resection and quality of life will be evaluated.

Eligibility criteria:
inclusion criteria: * suspected symptomatic or progressively growing pituitary adenoma * informed consent exclusion criteria: * prolactinoma * no follow-up possible * emergency surgery without informed consent or without intraoperative mri